|
Match
|
Document |
Document Title |
|
|
7534772 |
Methods for enhancing antibody-induced cell lysis and treating cancer
The invention relates to methods and products for treating cancer. In particular the invention relates to combinations of nucleic acids and antibodies for the treatment and prevention of cancer....
|
|
|
7534430 |
Use of IL-12 and IL-12 antagonists in the treatment of autoimmune diseases
Method of treating autoimmune conditions are disclosed comprising administering to a mammalian subject IL-12 or an IL-12 antagonist. In certain preferred embodiments the autoimmune condition is one...
|
|
|
7534427 |
Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
The invention is directed to a method for treating a treating and diagnosing a B cell-related disease, T cell-related disease or an autoimmune disease in a mammal by concurrently or sequentially...
|
|
|
7534432 |
Methods of treating musculodegenerative disease with an antibody that binds growth differentiation factor-8
Growth differentiation factor-8 (GDF-8) is disclosed along with its polynucleotide sequence and amino acid sequence. Also disclosed are diagnostic and therapeutic methods of using the GDF-8...
|
|
|
7534433 |
Method for improving body weight gain and feed conversion efficiency in animals
A method for improving body weight gain and increasing feed conversion efficiency of in animals by feeding the animals a diet containing antibodies against anti-nutritional factors in food.
|
|
|
7534431 |
Methods and compositions for administering therapeutic and diagnostic agents
Methods and compositions are described for targeting therapeutic and diagnostic molecules to particular types of cells using targeting antibodies or other targeting moeities.
|
|
|
7534869 |
Small and intermediate conductance, calcium-activated potassium channels and uses thereof
This invention relates to small and intermediate conductance, calcium-activated potassium channel proteins. More specifically, the invention relates to compositions and methods for making and...
|
|
|
7534428 |
Antibodies to tumor necrosis factor receptors 6α and 6β
The present invention relates to novel Tumor Necrosis Factor Receptor proteins. In particular, isolated nucleic acid molecules are provided encoding the human TNFR-6α & -6β proteins. TNFR-6α &...
|
|
|
7531170 |
Methods of treating OX40 mediated recall immune responses and agents useful for identifying same
T cell memory can persist in the absence of antigen. However, some memory cells by default are subject to signals accompanying periodic antigen exposure. OX40 is essential to the extent and...
|
|
|
7531168 |
Method for downmodulating immune response in type I diabetes
The instant invention provides compositions and methods for downmodulation of immune responses, e.g., autoimmune responses. For example, methods of downmodulating an immune response using agents...
|
|
|
7531174 |
Cripto blocking antibodies and uses thereof
The invention provides Cripto blocking antibodies, or biologically functional fragments thereof, and uses thereof. Antibodies which bind Cripto and modulate Cripto signaling are provided....
|
|
|
7531163 |
Enrichment methods for the detection of pathogens and other microbes
The present invention provides novel enrichment, testing and detection methods for detection of pathogens or other microbes in a food, water, wastewater, industrial, pharmaceutical, botanical,...
|
|
|
7531633 |
Staphylococcus antibodies
A negatively-charged Staphylococcus antigen contains amino acids and a N-acetylated hexosamine as a major carbohydrate component. The antigen is common to many coagulase-negative strains of ...
|
|
|
7531175 |
Methods for modulation of immune responses using humanized immunoglobulins reactive with B7-1 molecules
The invention relates to humanized anti-B7-2 and anti-B7-1 antibodies, wherein each comprise a variable region of non-human origin and at least a portion of an immunoglobulin of human origin. The...
|
|
|
7531169 |
High affinity anti-human IgE antibodies
The invention relates to high affinity human monoclonal antibodies, particularly those directed against isotypic determinants of immunoglobulin E (IgE), as well as direct equivalents and...
|
|
|
7531178 |
Immunoadhesin comprising a glycoprotein VI domain
The present invention provides a fusion protein comprising (1) the extracellular domain of glycoprotein VI or a variant thereof that is functional for binding to collagen and (b) the Fc domain of...
|
|
|
7531177 |
Surface protein of leptospira
The invention relates to Leptospiral surface proteins, and the nucleic acid molecules which encode them. Various uses are described, including immunoprophylactic, diagnostic and therapeutic methods.
|
|
|
7531171 |
Antibodies to non-functional P2X7 receptor
The present invention provides antibodies that specifically bind to P2X 7 receptors and distinguish between function and non-functional P2X 7 receptors, pharmaceutical compositions and kits...
|
|
|
7527788 |
Desaturase antigen of Mycobacterium tuberculosis
Antibodies that bind to the M. tuberculosis Des protein are provided.
|
|
|
7527790 |
Methods of reducing bone absorption comprising administering an antibody that binds OBM
Novel proteins and polypeptides binding to osteoclastogenesis inhibitory factor (OCIF) (OCIF-binding molecules, OBMs) and nucleic acids encoding these proteins and polypeptides are provided....
|
|
|
7527791 |
Humanized anti-TGF-beta antibodies
Humanized anti-TGF-beta antibodies are provided, as well as methods for their preparation and use, including methods for treating TGF-beta disorders, for example, cancer. Also provided are articles...
|
|
|
7527786 |
Methods for inhibiting the growth of cancer cells expressing PSCA
The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade...
|
|
|
7524650 |
Antibodies directed against hepatitis C virus E1E2 complex, compositions of HCV particles, and pharmaceutical compositions
New conformational antibodies are directed against HCV and more particularly to monoclonal antibodies. Described compositions of particles are liable to be recognized by the antibodies, as are...
|
|
|
7524663 |
Covalently reactive transition state analogs and methods of use thereof
Improved methods for the production, selection and inhibition of catalytic antibodies are disclosed.
|
|
|
7524495 |
Inhibition of TACE or amphiregulin for the modulation of EGF receptor signal transactivation
The present invention relates to the modulation of transactivation of receptor tyrosine kinases by G protein or G protein-coupled receptor (GPCR) mediated signal transduction in a cell or an...
|
|
|
7524622 |
Methods for increasing production of IFN-gamma in natural killer cells expressing LLT1 receptor
Natural killer (NK) cells possess the inherent capacity to kill various tumor and virally infected cells. A large family of NK cell receptors belongs to the C-type lectin super-family. Genes in the...
|
|
|
7524496 |
***WITHDRAWN PATENT AS PER THE LATEST USPTO WITHDRAWN LIST***
Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant,...
|
|
|
7524497 |
Antibodies to PRO 1120 polypeptide
The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid...
|
|
|
7521045 |
Methods of inhibiting metastasis
Methods of inhibiting metastasis or maintenance of various cancers are provided. In particular, the method makes use of fact that certain trafficking of cancers depend upon identified proteins,...
|
|
|
7521040 |
Immunotherapy for humans
An immunotherapy useful for treating a cancer and/or treating and preventing a microbial infection is provided. A pharmaceutical composition which comprises a bacterial component as an effective...
|
|
|
7521055 |
Ferroportin1 antibodies and methods
Positional cloning has been carried out to identify the gene responsible for the hypochromic anemia of the zebrafish mutant weissherbst. The gene, ferroportin1, encodes a novel...
|
|
|
7521051 |
Methods of upmodulating adaptive immune response using anti-PD-1 antibodies
This disclosure provides antibodies and antigen-binding fragments that can act as agonists and/or antagonists of PD-1 (Programmed Death 1), thereby modulating immune responses in general, and those...
|
|
|
7517862 |
Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers for use in methods...
|
|
|
7517963 |
Tumour necrosis factor binding ligands
The present invention relates to ligands which bind to human tumor necrosis factor alpha (TNF) in a manner such that upon binding of these ligands to TNF the biological activity of TNF is modified....
|
|
|
7517524 |
Immunointeractive molecules
The present invention relates generally to immunointeractive molecules and more particularly antibodies which bind to vascular endothelial growth factor-B (VEGF-B) or its functional or structural...
|
|
|
7517967 |
Monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
The present invention relates to monoclonal antibody 1A7. This is an anti-idiotype produced by immunizing with an antibody specific for ganglioside GD2, and identifying a hybridoma secreting...
|
|
|
7517962 |
TWEAK receptor
The present invention provides the TWEAK receptor and methods for identifying and using agonists and antagonists of the TWEAK receptor. In particular, the invention provides methods of screening...
|
|
|
7517523 |
Anti-MIF antibodies
The present invention relates to compositions and methods for inhibiting the release and/or biological activity of migration inhibitory factor (MIF). In particular, the invention relates to the...
|
|
|
7514077 |
Methods of antagonizing signal transduction in dorsal root ganglion cells with IL-31 antagonists
Use of antagonists to IL-31 are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include...
|
|
|
7514066 |
Targeted combination immunotherapy of cancer and infectious diseases
The present invention is directed to methods for treating cancer wherein more than one therapeutic agent is used, with each of the therapeutic agents having different tumor-killing capabilities,...
|
|
|
7514538 |
Compositions and methods for the diagnosis and treatment of tumor
The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
|
|
|
7510840 |
Method of inhibiting growth or survival of a cell by providing an anti-108P5H8 antibody
A novel gene (designated 108P5H8) and its encoded protein, and variants thereof, are described wherein 108P5H8 exhibits tissue specific expression in normal adult tissue, and is aberrantly...
|
|
|
7510707 |
PAR, a novel marker gene for breast and prostate cancers
The present invention relates to a gene selectively expressed in malignant cells and associated with the development of androgen resistance in prostate cancer. Levels of the gene, termed “PAR”...
|
|
|
7510712 |
Methods of treating rheumatoid arthritis with 7C10 and 16C10 CD80-specific antibodies
The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and...
|
|
|
7510713 |
Methods of inducing immunosuppression by administering 7C10 and 16C10 CD80-specific antibodies
The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and...
|
|
|
7510710 |
Compositions of UCP inhibitors, Fas antibody, a fatty acid metabolism inhibitor and/or a glucose metabolism inhibitor
Systems and methods for treating inflammatory and proliferative diseases, and wounds, using as a pharmacon a UCP and/or Fas antibody or other inhibitor, or combination thereof, and a...
|
|
|
7510711 |
Methods for the treatment of cancer using anti-CD40 antibodies
The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies of the immune system. The methods of the...
|
|
|
7510708 |
Disruption of the REG pathway
Disruption of the Reg signalling pathway permits spontaneous and therapeutic induction of pro-apoptotic signals to be more effective. Disruption can be accomplished by means of antibodies,...
|
|
|
7504106 |
Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis
A method for treating patients with renal failure includes administering to them an effective amount of antibody or of a functional equivalent thereof to at least two of urea, creatinine, tumor...
|
|
|
7504102 |
Anti-αvβ3 humanized monoclonal antibodies
This invention relates to novel humanized and other recombinant or engineered antibodies or monoclonal antibodies to the vitronectin α v β 3 receptor and to the genes encoding same. Such...
|